Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated, a biotechnology company, focuses on the discovery and early-stage development of pharmaceuticals for.
Launch date
Employees
Market cap
€1.7b
Enterprise valuation
€1.5b (Public information from Sep 2024)
Share price
$102.8 LGND
San Diego California (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 186m | 277m | 196m | 131m | 154m | 180m | 215m |
% growth | 55 % | 49 % | (29 %) | (33 %) | 17 % | 17 % | 19 % |
EBITDA | 32.0m | 117m | 8.7m | 51.2m | 85.9m | 140m | 168m |
% EBITDA margin | 17 % | 42 % | 4 % | 39 % | 56 % | 78 % | 78 % |
Profit | (3.0m) | 57.6m | (33.4m) | 52.2m | 49.2m | 60.6m | 87.6m |
% profit margin | (2 %) | 21 % | (17 %) | 40 % | 32 % | 34 % | 41 % |
EV / revenue | 8.6x | 9.3x | 5.8x | 9.5x | 12.6x | 10.7x | 9.0x |
EV / EBITDA | 50.0x | 22.0x | 129.2x | 24.3x | 22.5x | 13.8x | 11.5x |
R&D budget | 59.4m | 69.0m | 36.1m | 24.5m | - | - | - |
R&D % of revenue | 32 % | 25 % | 18 % | 19 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Seed | ||
N/A | N/A | IPO | |
N/A | $225m | Post IPO Debt | |
* | N/A | $650m | Post IPO Convertible |
N/A | N/A | - | |
Total Funding | - |
Recent News about Ligand Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
Investments by Ligand Pharmaceuticals
Editexited
ACQUISITION by Ligand Pharmaceuticals Sep 2008
ACQUISITION by Ligand Pharmaceuticals Aug 2020
ACQUISITION by Ligand Pharmaceuticals Oct 2017
ACQUISITION by Ligand Pharmaceuticals Oct 2009
ACQUISITION by Ligand Pharmaceuticals Dec 2009
exited
ACQUISITION by Ligand Pharmaceuticals Jul 2024